Aurogra-100 Aurochem Pharmaceuticals

£25.00

Aurogra-100 sildenafil citrate from Aurochem Pharmaceuticals is a phosphodiesterase type 5 inhibitor studied in cardiovascular and smooth muscle research applications.

 

  • 30 days easy returns
  • Order yours before 2.30pm for same day dispatch
Aurogra-100 Aurochem Pharmaceuticals
Aurogra-100 Aurochem Pharmaceuticals
£25.00

[wpforms id=”1190″ title=”true” description=”Request a call back”]

Compound Profile: Aurogra-100 Aurochem Pharmaceuticals

Aurogra-100 is a phosphodiesterase type 5 (PDE5) inhibitor manufactured by Aurochem Pharmaceuticals, containing sildenafil citrate as the active pharmaceutical ingredient. This compound operates through selective inhibition of cyclic guanosine monophosphate-specific phosphodiesterase type 5, leading to increased cyclic GMP levels in smooth muscle tissue research models. Sildenafil citrate represents one of the most extensively studied PDE5 inhibitors in cardiovascular research applications, with comprehensive pharmacological data available across multiple research paradigms. Researchers investigating vascular smooth muscle function, nitric oxide pathway modulation, and cyclic nucleotide signalling mechanisms frequently utilise this compound in controlled laboratory settings.

Laboratory Research Applications

Research scientists examine Aurogra-100 in studies focused on vascular biology, smooth muscle contractility mechanisms, and endothelial function assessment. The compound demonstrates selective affinity for PDE5 enzymes over other phosphodiesterase subtypes, making it valuable for investigating specific cyclic GMP-mediated cellular processes. Cardiovascular researchers study its effects on pulmonary arterial pressure regulation in animal models, while cell biologists investigate its impact on smooth muscle cell proliferation and migration pathways. Additionally, researchers exploring nitric oxide signalling cascades and their role in various physiological processes utilise this compound extensively. Studies examining the relationship between PDE5 inhibition and vascular remodelling frequently incorporate sildenafil citrate as a research tool. Many academic institutions and commercial research laboratories stock this compound for ongoing projects related to Stroid UK Shop in vascular biology. Investigators examining erectile dysfunction mechanisms also utilise this compound alongside studies involving selective androgen receptor modulators and peptide research compounds.

Technical Specifications

Aurogra-100 Research Specifications
Parameter Value
Active Ingredient Sildenafil Citrate
CAS Number 171599-83-0
Molecular Formula C₂₈H₃₈N₆O₁₁S
Molecular Weight 666.7 g/mol
Manufacturer Aurochem Pharmaceuticals
Storage Conditions Room temperature, dry environment

Research Compliance Statement

Aurogra-100 is supplied strictly for in-vitro laboratory research purposes only. This product is not intended for human consumption, therapeutic use, or any applications outside controlled research environments. Researchers must ensure appropriate laboratory protocols and safety measures are implemented when handling this compound. All studies should be conducted in accordance with institutional guidelines and applicable regulations governing research chemical use in laboratory settings.

Related